Oxycodone hydrochloride hydrate controlled-release - Daiichi Sankyo
Alternative Names: DS-5058b; Oxycodone hydrochloride trihydrateLatest Information Update: 08 Jan 2022
At a glance
- Originator Daiichi Sankyo Company
- Class Alkaloids; Morphine derivatives; Opioid analgesics; Small molecules
- Mechanism of Action Opioid delta receptor agonists; Opioid kappa receptor agonists; Opioid mu receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Pain
Most Recent Events
- 28 Sep 2018 No recent reports of development identified for phase-I development in Pain(In volunteers) in Japan (PO, Tablet)
- 31 May 2018 Daiichi Sankyo completes a phase I bioequivalence trial in healthy volunteers in Japan (JapicCTI-173793)
- 30 Nov 2017 Daiichi Sankyo plans a phase I bioequivalence trial in healthy volunteers in Japan (JapicCTI-173793)